Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

The pneumococcal conjugate vaccine – codenamed PCV21/GBP410 ... slightly down on the same period of 2023. MSD (known as Merck & Co in the US and Canada), meanwhile, recorded $647 million ...

Prior to COVID-19, pneumococcal vaccines were the largest vaccine market worldwide – estimated at around $8 billion – with Prevnar capturing almost $6 billion of that total in 2020 from its ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Merck & Co. is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical giant.

Robert F. Kennedy Jr., President Trump’s nominee to be health secretary, would have oversight power over the vaccine’s maker, Merck, if confirmed. By Christina Jewett and Sheryl Gay Stolberg ...

Merck said its board authorized an additional $10 billion share repurchase authorization, which has no time limit for completion. The maker of medicines and vaccines has a market cap of $247.75 ...

Co., Inc. (NYSE:MRK), a global healthcare leader, declared on Monday a quarterly dividend and a substantial stock repurchase ...

In a report released on January 24, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...